Frontiers in Cardiovascular Medicine · 2023 · 11 citations · 31 references
Life SciencesCardiologyClinical PharmacologyMetabolomicsPreventive CardiologyAmino Acid MetabolomicsMass Spectrometry-based MetabolomicsMetabolite ProfilingMetabolite QuantificationTargeted MetabolomicsUntargeted MetabolomicsAtherosclerotic Risk AssessmentAtherosclerotic Risk StratificationDisease Metabolite ProfilingMetabolomic Biomarker DiscoveryRisk Score DevelopmentTargeted Metabolite ProfilingTargeted Metabolomics AnalysisUntargeted Metabolomics Analysis
Background The intermediate metabolites associated with the development of atherosclerotic cardiovascular disease (ASCVD) remain largely unknown. Thus, we conducted a large panel of metabolomics profiling to identify the new candidate metabolites that were associated with 10-year ASCVD risk. Methods Thirty acylcarnitines and twenty amino acids were measured in the fasting plasma of 1,102 randomly selected individuals using a targeted FIA-MS/MS approach. The 10-year ASCVD risk score was calculated based on 2013 ACC/AHA guidelines. Accordingly, the subjects were stratified into four groups: low-risk ( n = 620), borderline-risk ( n = 110), intermediate-risk ( n = 225), and high-risk ( n = 147). 10 factors comprising collinear metabolites were extracted from principal component analysis. Results C 4 DC, C 8:1 , C 16 OH, citrulline, histidine, alanine, threonine, glycine, glutamine, tryptophan, phenylalanine, glutamic acid, arginine, and aspartic acid were significantly associated with the 10-year ASCVD risk score ( p -values ≤ 0.044). The high-risk group had higher odds of factor 1 (12 long-chain acylcarnitines, OR = 1.103), factor 2 (5 medium-chain acylcarnitines, OR = 1.063), factor 3 (methionine, leucine, valine, tryptophan, tyrosine, phenylalanine, OR = 1.074), factor 5 (6 short-chain acylcarnitines, OR = 1.205), factor 6 (5 short-chain acylcarnitines, OR = 1.229), factor 7 (alanine, proline, OR = 1.343), factor 8 (C 18:2 OH, glutamic acid, aspartic acid, OR = 1.188), and factor 10 (ornithine, citrulline, OR = 1.570) compared to the low-risk ones; the odds of factor 9 (glycine, serine, threonine, OR = 0.741), however, were lower in the high-risk group. “D-glutamine and D-glutamate metabolism”, “phenylalanine, tyrosine, and tryptophan biosynthesis”, and “valine, leucine, and isoleucine biosynthesis” were metabolic pathways having the highest association with borderline/intermediate/high ASCVD events, respectively. Conclusions Abundant metabolites were found to be associated with ASCVD events in this study. Utilization of this metabolic panel could be a promising strategy for early detection and prevention of ASCVD events.
31
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
David C. Goff, Donald M. Lloyd‐Jones, Glen C. Bennett et al. · Circulation · 2013 · 3.7K citations · Full text
Metabolite profiles and the risk of developing diabetes
Thomas J. Wang, Martin G. Larson, Ramachandran S. Vasan et al. · Nature Medicine · 2011 · 3.1K citations · Full text
Novel biomarkers for pre‐diabetes identified by metabolomics
Rui Wang‐Sattler, Zhonghao Yu, Christian Herder et al. · Molecular Systems Biology · 2012 · 708 citations · Full text
Metabolite Profiling and Cardiovascular Event Risk
Peter Würtz, Aki S. Havulinna, Pasi Soininen et al. · Circulation · 2015 · 697 citations · Full text